Arshad M. Khanani, MD, MA, FASRS

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Khanani about new retinal gene therapy trials, covering safety, delivery, and ways to reduce treatment burden.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.